Virchows Arch
Virchows Archiv
0945-6317
1432-2307
Springer-Verlag
Berlin/Heidelberg


1888716
17252232
348
10.1007/s00428-006-0348-5
Original Article


Expression microarray analysis of papillary thyroid carcinoma and benign thyroid tissue: emphasis on the follicular variant and potential markers of malignancy

Finn
S. P.

1

Smyth
P.

1

Cahill
S.

1

Streck
C.

5

O’Regan
E. M.

2

Flavin
R.

1

Sherlock
J.

5

Howells
D.

5

Henfrey
R.

5

Cullen
M.

4

Toner
M.

2

Timon
C.

3

O’Leary
J. J.

1

Sheils
O. M.

+353-1-8963284
+353-1-8963285
osheils@tcd.ie

1
6

1
Department of Histopathology, University of Dublin, Trinity College, Dublin, Ireland 
2
Dublin Dental School and Hospital, Dublin, Ireland 
3
Department of Otolaryngology, St. James’s Hospital, Dublin, Ireland 
4
Department of Endocrinology, St James’s Hospital, Dublin, Ireland 
5
Applied Biosystems, Foster City, CA USA 
6
Department of Histopathology, Institute of Molecular Medicine, Trinity Centre for Health Sciences, St. James’s Hospital, Dublin 8, Ireland 

25
1
2007

3
2007

450
3
249
260
27
7
2006

2
11
2006


© Springer-Verlag 2007

The most common sub-variant of papillary thyroid carcinoma (PTC) is the so-called follicular variant (FVPTC), which is a particularly problematic lesion and can be challenging from a diagnostic viewpoint even in resected lesions. Although fine needle aspiration cytology is very useful in the diagnosis of PTC, its accuracy and utility would be greatly facilitated by the development of specific markers for PTC and its common variants. We used the recently developed Applied Biosystems 1700 microarray system to interrogate a series of 11 benign thyroid lesions and conditions and 14 samples of PTC (six with classic morphology and eight with follicular variant morphology). TaqMan® reverse transcriptase-polymerase chain reaction was used to validate the expression portfolios of 50 selected transcripts. Our data corroborates potential biomarkers previously identified in the literature, such as LGALS3, S100A11, LYN, BAX, and cluster of differentiation 44 (CD44). However, we have also identified numerous transcripts never previously implicated in thyroid carcinogenesis, and many of which are not represented on other microarray platforms. Diminished expression of metallothioneins featured strongly among these and suggests a possible role for this family as tumour suppressors in PTC. Fifteen transcripts were significantly associated with FVPTC morphology. Surprisingly, these genes were associated with an extremely narrow repertoire of functions, including the major histocompatibility complex and cathepsin families.

Keywords
Papillary thyroid carcinoma
Biomarker
Follicular variant
Microarray
TaqMan® PCR

issue-copyright-statement
© Springer-Verlag 2007




Introduction
Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy and encompasses a variety of morphological/architectural variants, all of which are characterized by a distinctive nuclear appearance. In recent years, PTC has become an important paradigm of solid tumour molecular pathogenesis principally arising from intensive investigation prompted by the Chernobyl accident.
12
13
35
42
21
30
22
32
11
39
42
]. Nevertheless, the utility of these genetic lesions to diagnostic pathology and clinical practice has remained negligible.
2
6
9
10
20
28
]. The discovery of such a biomarker or panel of biomarkers allied to the gold standard triage method of fine needle aspiration cytology (FNAC) would represent a significant advancement in the treatment of the solitary thyroid nodule.
25
45
].
It is clear that this is a complex and contentious area, and that further work needs to be done to ascertain the underlying molecular biology of this particular variant. Recently, inroads into elucidation of molecular pathways underpinning PTC have been carried out using microarray studies. The overriding objective of these investigations was to identify clinically useful biomarkers. However, the majority of these studies have analysed PTC as though it were a homogenous singular entity without deference in a detailed manner to sub-variants and, in particular, the most common variant (FVPTC). The identification of specific biomarkers of FVPTC and a deeper understanding of its origins are clearly warranted.
The aim of this expression microarray study using a novel microarray platform was twofold: to identify markers that distinguish PTC from benign thyroid tissue and lesions and, secondly, to identify potential markers and further explore the molecular pathology of FVPTC.

Materials and methods
Patients and tissue samples
24
1
Table 1
Sample cohort

Identifier
Diagnosis


N1
Normal thyroid tissue

N2
Normal thyroid tissue

N3
Lymphocytic thyroiditis

N4
Nodular hyperplasia

N5
Follicular adenoma

N6
Nodular hyperplasia with focal lymphocytic thyroiditis

N7
Nodular hyperplasia

N8
Follicular adenoma

N9
Nodular hyperplasia

N10
Follicular adenoma

N11
Grave’s thyroiditis

T1
Solid/FVPTC

T2
FVPTC

T3
PTC classic morphology

T4
FVPTC-oxyphil

T5
FVPTC

T6
FVPTC

T7
PTC classic morphology

T8
FVPTC

T9
PTC classic morphology

T10
FVPTC

T11
PTC classic morphology

T12
FVPTC

T13
PTC classic morphology

T14
PTC classic morphology



List of the 11 benign and 14 malignant lesions that were used in this study.
FV
PTC
 papillary thyroid carcinoma




RNA isolation and characterization
Samples were ground in liquid nitrogen and homogenised in RLT buffer (Qiagen, UK). RNA was then extracted using the RNeasy Mini Kit with optional on-column RNase-free DNase digestion (Qiagen) according to the manufacturer’s instructions. RNA quantity was determined using UV spectrophotometry. RNA quality was assessed using the RNA 6000 Nano LabChip® Kit in conjunction with the Agilent 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany).

Microarray analysis
Applied Biosystems Human Genome Survey Arrays were used to analyse the transcriptional profiles of thyroid RNA samples in this study. Digoxigenin-UTP-labelled cRNA was generated and linearly amplified from 5 μg of total RNA using Applied Biosystems Chemiluminescent RT-IVT Labelling Kit v 2.0 using manufacturer’s protocol. 10 μg of labelled cRNA were hybridized to each pre-hybed microarray in a 1.5-ml volume at 55°C for 16 h. Array hybridization and chemiluminescence detection were performed using Applied Biosystems Chemiluminescence Detection Kit following manufacturer’s protocol. Images were collected for each microarray using the 1700 analyser. Images were auto-gridded and the chemiluminescent signals were quantified, corrected for background and spot, and spatially normalized.

TaqMan® PCR validation
23
] with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an endogenous control/reference assay.

Statistical analysis
Microarrays were analysed using Spotfire DecisionSite™ for Functional Genomics (Spotfire AB, Goteborg, Sweden) and R version 1.9.1, a free language and environment for statistical computing and graphics (R Development Core Team, 2004). Arrays were initially normalized, and genes were deemed undetectable and, therefore, excluded from final gene lists if they had a signal-to-noise ratio of less than three (S/N < 3) in greater than 18 of the 25 arrays.
p
p
3
p
http://www.pantherdb.org
). Correlations between microarray and TaqMan® expression data were measured using the Pearson coefficient.


Results
1
p
2
Table 2
Genes differentially expressed in malignant vs benign thyroid tissue

Gene Name
Gene Symbol
p
 value
1700 probe ID


Genes up-regulated in malignant vs benign

 Active BCR-related gene
ABR
0.014482
154399

 Adaptor-related protein complex 2, alpha 1 subunit
AP2A1
0.0312
115368

 Apoptosis, caspase activation inhibitor
AVEN
0.030998
203738

 BCL2-associated X protein
BAX
0.009782
146510

 BH3 interacting domain death agonist
BID
0.021424
131216

 Brain abundant, membrane attached signal protein 1
BASP1
0.024214
198318

 Brain acyl-CoA hydrolase
BACH
0.014566
133876

 Bromodomain adjacent to zinc finger domain, 1A
BAZ1A
0.03538
209809

 Calcium/calmodulin-dependent protein kinase I
CAMK1
0.041887
157712

 Cathepsin S
CTSS
0.046544
105790

 CD44 antigen (homing function and Indian blood group system)
CD44
0.044181
133604

 Chemokine (C-X-C motif) ligand 16
CXCL16
0.043234
199059

 Chromosome 1 open reading frame 38
C1orf38
0.049072
202924

 CLIP-170-related protein
CLIPR-59
0.023629
102205

 Docking protein 1, 62 kDa (downstream of tyrosine kinase 1)
DOK1
0.041898
204989

 Epidermodysplasia verruciformis 1
EVER1
0.003348
175569

 FXYD domain containing ion transport regulator 5
FXYD5
0.01444
154607

 FXYD domain containing ion transport regulator 5
FXYD5
0.023629
112771

 Galactose-4-epimerase, UDP
GALE
0.047363
141143

 Genethonin 1
GENX-3414
0.016836
124360

 Hypothetical gene BC008967
BC008967
0.015683
108526

 Hypothetical protein FLJ10849
FLJ10849
0.013822
224983

 Hypothetical protein FLJ22531
FLJ22531
0.024391
145918

 Hypothetical protein MGC4607
MGC4607
0.006507
211836

 Intercellular adhesion molecule 1 (CD54), human rhinovirus receptor
ICAM1
0.028746
109070

 Jun dimerization protein p21SNFT
SNFT
0.043301
144215

 Lectin, galactoside-binding, soluble, 3 (galectin 3)
LGALS3
0.034491
179836

 Major vault protein
MVP
0.0312
212354

 Matrix metalloproteinase 14 (membrane-inserted)
MMP14
0.038682
152076

 Milk fat globule-EGF factor 8 protein
MFGE8
0.02392
144588

 Mst3 and SOK1-related kinase
MST4
0.042028
112198

 neuronal cell adhesion molecule
NRCAM
0.011178
106462

 Phospholipase D3
PLD3
0.034491
143388

 Promyelocytic leukemia
PML
0.016018
217558

 Protein inhibitor of activated STAT protein PIASy
PIASY
0.00536
153434

 Protein tyrosine phosphatase, receptor type, E
PTPRE
0.048653
221568

 Rho GDP dissociation inhibitor (GDI) beta
ARHGDIB
0.043853
143589

 S100 calcium binding protein A11 (calgizzarin)
S100A11
0.019933
145550

 Similar to rat tricarboxylate carrier-like protein
BA108L7.2
0.025387
179870

 SP110 nuclear body protein
SP110
0.0312
113484

 Stimulated by retinoic acid gene 6
FLJ12541
0.043234
193986

 Syndecan 3 (N-syndecan)
SDC3
0.048804
143980

 Tax interaction protein 1
TIP-1
0.006673
119665

 TBC1 domain family, member 2
TBC1D2
0.029907
205982

 Tenascin C (hexabrachion)
TNC
0.032355
143831

 Thymosin, beta 4, Y chromosome
TMSB4Y
0.040937
193911

 Tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase  inhibitor)
TIMP1
0.032306
134692

 Topoisomerase (DNA) II alpha 170 kDa
TOP2A
0.040937
135302

 Transforming growth factor, beta 1
TGFB1
0.016836
170749

 Transgelin 2
TAGLN2
0.031971
172296

 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta  polypeptide
YWHAH
0.039009
188379

 v-yes-1 Yamaguchi sarcoma viral related oncogene homolog
LYN
0.016175
194134

Genes down-regulated in malignant vs benign

 Aldehyde oxidase 1
AOX1
0.003227
106573

 Ankyrin 2, neuronal
ANK2
0.035357
155780

 Aspartate beta-hydroxylase
ASPH
0.002064
221656

 Aspartate beta-hydroxylase
ASPH
0.019666
114180

 ATPase, Cu++ transporting, beta polypeptide
ATP7B
0.044511
198852

 Brain-specific protein p25 alpha
p25
0.023629
120622

 Casein kinase
LOC149420
0.022382
149347

 Cellular retinoic acid binding protein 1
CRABP1
0.008315
100295

 Centromere protein J
CENPJ
0.0312
164563

 Ceroid-lipofuscinosis, neuronal 5
CLN5
0.011021
205999

 Chloride channel Kb
CLCNKB
0.040418
176266

N
-acetylgalactosaminyltransferase
ChGn
0.013148
101140

 Chromosome 11 open reading frame 8
C11orf8
0.001977
174025

 Chromosome 11 open reading frame 8
C11orf8
0.004148
108279

 Chromosome 21 open reading frame 4
C21orf4
0.0042
156895

 Clusterin-like 1 (retinal)
CLUL1
0.019631
186062

 Component of oligomeric golgi complex 3
COG3
0.003664
129212

 Coxsackie virus and adenovirus receptor
CXADR
0.004648
108284

 Crystallin, alpha B
CRYAB
0.030418
190274

O
-acetylesterase homolog
CSE-C
0.040993
213856

l
-xylulose reductase
DCXR
0.001977
103350

 DnaJ (Hsp40) homolog, subfamily B, member 4
DNAJB4
0.043853
103618

S. cerevisiae
)
ERO1LB
0.013962
207998

 Extracellular link domain containing 1
XLKD1
0.039738
195865

 Family with sequence similarity 13, member A1
FAM13A1
0.019631
116936

 Fatty acid binding protein 4, adipocyte
FABP4
0.014832
150137

 Fc fragment of IgG binding protein
FCGBP
0.001965
118361

 Fibroblast growth factor receptor 2
FGFR2
0.0042
110548

 FLJ35740 protein
FLJ35740
0.020224
101102

 Friedreich ataxia region gene X123
X123
0.032602
133505

 Glutamate-ammonia ligase (glutamine synthase)
GLUL
0.014649
175147

l
-arginine/glycine amidinotransferase)
GATM
0.013962
111904

 Glycoprotein M6A
GPM6A
0.011739
215326

 Growth hormone receptor
GHR
0.017721
190306

 HLA complex group 4
HCG4
0.025807
191199

 Hypothetical protein BC009561
LOC119710
0.003227
211319

 Hypothetical protein BC019238
LOC120379
0.013438
201200

 Hypothetical protein FLJ13204
FLJ13204
0.003227
145066

 Hypothetical protein FLJ13842
FLJ13842
0.016448
208504

 Hypothetical protein FLJ14054
FLJ14054
0.049072
202017

 Hypothetical protein FLJ20154
FLJ20154
0.014428
143310

 Hypothetical protein FLJ20513
FLJ20513
0.019493
154130

 Hypothetical protein FLJ32110
FLJ32110
0.015507
229492

 Hypothetical protein FLJ32343
FLJ32343
0.012208
116902

 Hypothetical protein FLJ33516
FLJ33516
0.03965
224600

 Hypothetical protein FLJ37549
FLJ37549
0.001956
218577

 Hypothetical protein FLJ39378
FLJ39378
0.005853
163223

 Hypothetical protein FLJ40021
FLJ40021
0.023629
174198

 Hypothetical protein LOC134285
LOC134285
0.018694
163671

 Hypothetical protein MGC10946
MGC10946
0.022382
195982

 Hypothetical protein MGC14425
MGC14425
0.015445
161569

 Hypothetical protein MGC17299
MGC17299
0.026062
168452

 Hypothetical protein MGC17943
MGC17943
0.0042
147296

 Hypothetical protein MGC23980
MGC23980
0.018694
224619

 Hypothetical protein MGC24047
MGC24047
0.001956
138122

 Hypothetical protein MGC33607
MGC33607
0.033547
100645

 Ionized calcium binding adapter molecule 2
IBA2
0.0042
179489

 KIAA0390 gene product
KIAA0390
0.014832
119936

 KIAA0703 gene product
KIAA0703
0.032602
146652

 Lectin, mannose-binding, 1
LMAN1
0.031092
179632

 Leiomodin 1 (smooth muscle)
LMOD1
0.022352
120404

 Likely ortholog of rat SNF1/AMP-activated protein kinase
SNARK
0.044605
157942

 LIM domain kinase 2
LIMK2
0.002409
151439

 Low density lipoprotein-related protein 1B (deleted in tumors)
LRP1B
0.00536
209464

 Low density lipoprotein-related protein 2
LRP2
0.040937
114919

 Matrilin 2
MATN2
0.0042
167316

 Metallothionein 1A (functional)
MT1A
0.013822
204773

 Metallothionein 1A (functional)|metallothionein 1E (functional)|metallothionein 1K| metallothionein 2A
MT1A|MT2A|MT1E|MT1K
0.027037
146368

 Metallothionein 1A (functional)|metallothionein 1E (functional)|metallothionein 2A| metallothionein 1K
MT1A|MT2A|MT1K|MT1E
0.043841
182305

 Metallothionein 1A (functional)|metallothionein 2A|metallothionein 1K| metallothionein 1E (functional)
MT1A|MT1K|MT1E|MT2A
0.011739
223856

 Metallothionein 1B (functional)
MT1B
0.019631
174119

 Metallothionein 1F (functional)
MT1F
0.024726
144569

 Metallothionein 1G
MT1G
0.0192
164525

 Metallothionein 1G
MT1G
0.03965
171539

 Metallothionein 1J
MT1J
0.008315
227956

 Metallothionein 1X
MT1X
0.008335
119685

 Metallothionein 1X
MT1X
0.010748
173072

 Metallothionein IV
MT4
0.007447
223241

 Methionine adenosyltransferase II, alpha
MAT2A
0.014428
158350

 Mitogen-activated protein kinase 4
MAPK4
0.042306
131252

 Myc-induced nuclear antigen, 53 kDa
MINA53
0.011959
130284

 NIMA (never in mitosis gene a)- related kinase 11
NEK11
0.001965
194628

 Otospiralin
LOC150677
0.018694
182360

 PDZ/coiled-coil domain binding partner for the rho-family GTPase TC10
PIST
0.013822
103651

 Phospholipase A2 receptor 1, 180 kDa
PLA2R1
0.004029
134379

 Phospholipase C-like 1
PLCL1
0.022657
206894

 Phosphotidylinositol transfer protein, beta
PITPNB
0.014428
122698

 Polycystic kidney and hepatic disease 1 (autosomal recessive)-like 1
PKHD1L1
0.0042
199896

 Polymerase (DNA directed) iota
POLI
0.003227
167492

 Potassium channel, subfamily K, member 9
KCNK9
0.000849
108648

 Potassium channel-interacting protein 4
KCNIP4
0.011447
147058

 Potassium inwardly-rectifying channel, subfamily J, member 13
KCNJ13
0.008972
124187

 pp21 Homolog
LOC51186
0.004326
127636

 Pre-B cell leukemia transcription factor 4
PBX4
0.030311
199118

 Protein kinase, cAMP-dependent, catalytic, beta
PRKACB
0.023863
198878

 Protein phosphatase 4, regulatory subunit 2|hypothetical protein LOC151987
PPP4R2|LOC151987
0.011338
200919

 RAB23, member RAS oncogene family
RAB23
0.000659
122394

 Ras association (RalGDS/AF-6) domain family 6
RASSF6
0.048804
119072

 Sarcoglycan, delta (35 kDa dystrophin-associated glycoprotein)
SGCD
0.011178
120415

 Serum deprivation response (phosphatidylserine binding protein)
SDPR
0.011021
156433

 SH3 and multiple ankyrin repeat domains 2
SHANK2
0.043996
193906

 Solute carrier family 26, member 7
SLC26A7
0.0042
225067

 Solute carrier family 26, member 7
SLC26A7
0.005853
213530

 Solute carrier family 5 (iodide transporter), member 8
SLC5A8
0.031284
231731

 SPARC related modular calcium binding 2
SMOC2
0.021505
135930

 Syndecan 2 (heparan sulfate proteoglycan 1, cell surface-associated, fibroglycan)
SDC2
0.001258
209676

 Syntaxin 12
STX12
0.01117
199949

 T-box 22
TBX22
0.024297
177517

 Thioredoxin-like, 32 kDa
TXNL
0.001102
192552

 Thyroid stimulating hormone receptor
TSHR
0.02176
108606

 Tissue inhibitor of metalloproteinase 4
TIMP4
0.023629
184795

 Trefoil factor 3 (intestinal)
TFF3
0.004648
114445

 Trefoil factor 3 (intestinal)
TFF3
0.014428
100949

N
d
N
-acetylgalactosaminyltransferase 9 (GalNAc-T9)
GALNT9
0.031284
161042

S. pombe
)
WEE1
0.024101
123533

 WW domain containing oxidoreductase
WWOX
0.012208
224298

 WW domain containing oxidoreductase
WWOX
0.024101
135080

 Zinc finger protein 258
ZNF258
0.013962
225961

 Zinc finger protein 36, C3H type-like 2
ZFP36L2
0.018837
210469



p
p
 < 0.05) between the malignant and benign thyroid tissues.



1
Fig. 1
Hierarchical clustering of samples. This heat map shows the clustering of the 25 samples based on the 236 probes found to be differentially regulated in benign vs malignant thyroid tissue. Clustering was performed using the unweighted pair group method with arithmetic mean, with Euclidian distance as the similarity measure. Average value was used as the ordering function




p
p
 < 0.000001).
ANOVA tests were used to determine which genes were differentially regulated in the FVPTC cohort only. Fifteen genes were identified, including cluster of differentiation 14 (CD14), CD74, CTSC, CTSH, CTSS, DPP6, ETHE1, human leucocyte antigen A (HLA-A), HLA-DMA, HLA-DPB1, HLA-DQB1, HLA-DRA, osteoclast stimulating factor 1 (OSTF1), TDO2, and a previously uncharacterized gene (noname).
23
2
3
Fig. 2
n
n
 = 20) for six genes. Plots for those genes with multiple probes are also displayed where appropriate



Table 3
Correlation between TaqMan® and microarray data

Gene
r
 coefficient
p



Genes differentially expressed in FVPTC vs classic PTC

CD14
0.83
<0.0001

a

0.87
<0.0001


0.74
0.0002

CTSC
0.53
0.0170

CTSH
0.71
0.0005

CTSS
0.62
0.0037

DPP6
0.76
0.0001

ETHE1
0.30
0.2008

HLA-A
0.77
<0.0001

HLA-DMA
0.75
0.0001

HLA-DPB1
0.96
<0.0001

a

0.70
0.0006


0.63
0.0031

HLA-DRA
0.82
<0.0001

NONAME
−0.02
0.9323

OSTF1
0.15
0.5171

TDO2
0.68
0.0009

Genes differentially expressed in benign vs malignant

BAX
0.20
0.3997

CAMK1
0.17
0.4771

CD44
0.57
0.0094

CTSS
0.62
0.0037

CXADR
0.36
0.1152

FGFR2
0.84
<0.0001

GALE
0.54
0.0138

ICAM1
0.62
0.0038

LYN
0.45
0.0483

MAPK4
0.76
<0.0001

MMP14
0.36
0.1175

MT1F
0.92
<0.0001

a

0.68
0.0011


0.69
0.0007


0.70
0.0006

a

0.88
<0.0001


0.88
<0.0001

RAB23
0.70
0.0006

S100A11
0.61
0.0041

SDC2
0.34
0.1415

SDC3
0.57
0.0087

a

0.97
<0.0001


0.96
<0.0001

TGFB1
0.56
0.0098

TIMP1
0.73
0.0003

TIMP4
0.80
<0.0001

TOP2A
0.07
0.7769

TSHR
0.18
0.4440



Gene expression profiles for TaqMan® PCR and microarray results were compared using the Pearson coefficient.
a
Genes have more than one probe ID on microarray




Discussion
The primary aim of this study was to generate an overview of molecular markers of malignancy in PTC with a view to identifying discriminators between common sub-types (classic PTC and FVPTC), using genome-wide expression microarray technology validated by TaqMan® RT-PCR. To this end, lesions that were well characterized histologically were selected.
27
].
26
8
].
2
4
7
33
2
9
16
], none have detected so many as the current study.
31
36
17
] followed up their initial microarray experiment by showing that MT1G is down regulated in PTC via hypermethylation. The biological significance of low metallothionein expression in thyroid tumours is therefore still poorly understood; however, it is interesting to speculate that metallothioneins may have roles as tumour suppressors in thyroid carcinoma.
LGALS3
9
16
20
LYN
46
TFF3
2
9
16
CRABP1
9
16
BAX
2
MAPK4
28
CD44
16
TIMP1
20
FGFR2
9
S100A11
20
40
29
41
].
Correlation of highlighted features with the current state of knowledge of the molecular pathology of thyroid neoplasia goes some way towards providing an external validation of the data obtained from the AB1700 system. However, additional validation using TaqMan® RT-PCR was performed.
p
15
38
]. Where there was discordance in the data, it could be accounted for by differences in the sequences targeted by the TaqMan® target sequences and the microarray probe. In those cases, the array and pre-designed TaqMan assays interrogated different exons or alternative splice variants. This finding highlights the importance of matching the targets to be validated from microarray data sets.
2
3
3
).
34
34
19
47
18
37
19
] have drawn attention to aberrant expression of HLA-DRA in ret/PTC-activated PTC. Expression of HLA-DRA may in some way explain the propensity for PTC to metastasize to lymph nodes and often apparently reside there without markedly worsening prognosis.
43
44
1
14
5
14
], where it acts in association with CD44, another transcript showing increased expression in both classic morphology PTC and FVPTC.
A particular focus of this study was to compare transcriptome profiles for PTCs with classic morphology and FVPTC given the propensity for FVPTC lesions to prove problematic from a diagnostic perspective. Although the study confirms the close relationship between the two most common variants of PTC, a narrow portfolio of genes and, in particular, gene functions was elucidated in the FVPTC cohort. The targets identified are easily amenable to analysis by more established techniques such as TaqMan® RT-PCR, with associated potential as additional markers for application in the FNAC setting. Clearly, the potential biomarkers identified in this study will require prospective evaluation in the context of real clinical diagnostic situations in the future to consolidate their merit as adjunctive tests in the diagnostic setting and to validate their altered expression states in the pathobiology of PTC development.


Acknowledgement
Dr. Smyth and Dr. Finn contributed equally to this study.

References
1.
Amatschek
S

Koenig
U

Auer
H

Steinlein
P

Pacher
M

Gruenfelder
A

Dekan
G

Vogl
S

Kubista
E

Heider
KH

Stratowa
C

Schreiber
M

Sommergruber
W


Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes
Cancer Res
2004
264
844
856
10.1158/0008-5472.CAN-03-2361

14871811


2.
Barden
CB

Shister
KW

Zhu
B

Guiter
G

Greenblatt
DY

Zeiger
MA

Fahey
TJ


Classification of follicular thyroid tumors by molecular signature: results of gene profiling
Clin Cancer Res
2003
9
1792
1800

12738736


3.
Benjamini
Y

Yekutieli
D


The control of the false discovery rate in multiple testing under dependency
Ann Stat
2001
29
1165
1188
10.1214/aos/1013699998

Benjamini Y, Yekutieli D (2001) The control of the false discovery rate in multiple testing under dependency. Ann Stat 29:1165–1188 

4.
Cai
L

Wang
GJ

Xu
ZL

Deng
DX

Chakrabarti
S

Cherian
MG


Metallothionein and apoptosis in primary human hepatocellular carcinoma (HCC) from northern China
Anticancer Res
1998
18
4667
4672

9891538


5.
Castellone
MD

Celetti
A

Guarino
V

Cirafici
AM

Basolo
F

Giannini
R

Medico
E

Kruhoffer
M

Orntoft
TF

Curcio
F

Fusco
A

Melillo
RM

Santoro
M


Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells
Oncogene
2004
23
2188
2196
10.1038/sj.onc.1207322

14981541


6.
Cerutti
JM

Delcelo
R

Amadei
MJ

Nakabashi
C

Maciel
RM

Peterson
B

Shoemaker
J

Riggins
GJ


A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression
J Clin Invest
2004
113
1234
1242
10.1172/JCI200419617

15085203


7.
Deng
DX

Chakrabarti
S

Waalkes
MP

Cherian
MG


Metallothionein and apoptosis in primary human hepatocellular carcinoma and metastatic adenocarcinoma
Histopathology
1998
32
340
347
10.1046/j.1365-2559.1998.00348.x

9602331


8.
Ding
K

Lopez-Burks
M

Sanchez-Duran
JA

Korc
M

Lander
AD


Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells
J Cell Biol
2005
171
729
738
10.1083/jcb.200508010

16286510


9.
Finley
DJ

Arora
N

Zhu
B

Gallagher
L

Fahey
TJ


Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules
J Clin Endocrinol Metab
2004
89
3214
3223
10.1210/jc.2003-031811

15240595


10.
Finley
DJ

Zhu
B

Barden
CB

Fahey
TJ


Discrimination of benign and malignant thyroid nodules by molecular profiling
Ann Surg
2004
240
425
436
10.1097/01.sla.0000137128.64978.bc

15319714


11.
Finn
SP

Smyth
P

O’Leary
J

Sweeney
EC

Sheils
O


Ret/PTC chimeric transcripts in an Irish cohort of sporadic papillary thyroid carcinoma
J Clin Endocrinol Metab
2003
88
938
941
10.1210/jc.2002-021239

12574236


12.
Fusco
A

Grieco
M

Santoro
M

Berlingieri
MT

Pilotti
S

Pierotti
MA

Della Porta
G

Vecchio
G


A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases
Nature
1987
328
170
172
10.1038/328170a0

3600795


13.
Grieco
M

Santoro
M

Berlingieri
MT

Melillo
RM

Donghi
R

Bongarzone
I

Pierotti
MA

Della Porta
G

Fusco
A

Vecchio
G


PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas
Cell
1990
60
557
563
10.1016/0092-8674(90)90659-3

2406025


14.
Guarino
V

Faviana
P

Salvatore
G

Castellone
MD

Cirafici
AM

Falco
V

Celetti
A

Giannini
R

Basolo
F

Melillo
RM

Santoro
M


Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness
J Clin Endocrinol Metab
2005
90
5270
5278
10.1210/jc.2005-0271

15998773


15.
Hermann
S

Sturm
I

Mrozek
A

Klosterhalfen
B

Hauptmann
S

Dorken
B

Daniel
PT


Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma
Int J Cancer
2001
92
805
811
10.1002/ijc.1284

11351299


16.
Huang
Y

Prasad
M

Lemon
WJ

Hampel
H

Wright
FA

Kornacker
K

LiVolsi
V

Frankel
W

Kloos
RT

Eng
C

Pellegata
NS

Chapelle
A


Gene expression in papillary thyroid carcinoma reveals highly consistent profiles
Proc Natl Acad Sci USA
2001
98
15044
15049
10.1073/pnas.251547398

11752453


17.
Huang
Y

Chapelle
A

Pellegata
NS


Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma
Int J Cancer
2003
104
735
744
10.1002/ijc.11006

12640681


18.
Hunt
JL

Baloch
ZW

Barnes
L

Swalsky
PA

Trusky
CL

Sesatomi
E

Finkelstein
S

LiVolsi
VA


Loss of heterozygosity mutations of tumor suppressor genes in cytologically atypical areas in chronic lymphocytic thyroiditis
Endocr Pathol
2002
13
321
330
10.1385/EP:13:4:321

12665650


19.
Hwang
ES

Kim
DW

Hwang
JH

Jung
HS

Suh
JM

Park
YJ

Chung
HK

Song
JH

Park
KC

Park
SH

Yun
HJ

Kim
JM

Shong
M


Regulation of signal transducer and activator of transcription 1 (STAT1) and STAT1-dependent genes by RET/PTC (rearranged in transformation/papillary thyroid carcinoma) oncogenic tyrosine kinases
Mol Endocrinol
2004
18
2672
2684
10.1210/me.2004-0168

15297606


20.
Jarzab
B

Wiench
M

Fujarewicz
K

Simek
K

Jarzab
M

Oczko-Wojciechowska
M

Wloch
J

Czarniecka
A

Chmielik
E

Lange
D

Pawlaczek
A

Szpak
S

Gubala
E

Swierniak
A


Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications
Cancer Res
2005
65
1587
1597
10.1158/0008-5472.CAN-04-3078

15735049


21.
Kimura
ET

Nikiforova
MN

Zhu
Z

Knauf
JA

Nikiforov
YE

Fagin
JA


High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC–RAS–BRAF signaling pathway in papillary thyroid carcinoma
Cancer Res
2003
63
1454
1457

12670889


22.
Lima
J

Trovisco
V

Soares
P

Maximo
V

Magalhaes
J

Salvatore
G

Santoro
M

Bogdanova
T

Tronko
M

Abrosimov
A

Jeremiah
S

Thomas
G

Williams
D

Sobrinho-Simoes
M


BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas
J Clin Endocrinol Metab
2004
89
4267
4271
10.1210/jc.2003-032224

15356020


23.
Livak
KJ

Schmittgen
TD


Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method
Methods
2001
25
402
408
10.1006/meth.2001.1262

11846609


24.
Lloyd R, DeLellis R, Heitz P, Eng C (eds) (2004) Pathology and genetics of tumours of endocrine Organs. IARC Press

25.
Lloyd
RV

Erickson
LA

Casey
MB

Lam
KY

Lohse
CM

Asa
SL

Chan
JK

DeLellis
RA

Harach
HR

Kakudo
K

LiVolsi
VA

Rosai
J

Sebo
TJ

Sobrinho-Simoes
M

Wenig
BM

Lae
ME


Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma
Am J Surg Pathol
2004
28
1336
1340
10.1097/01.pas.0000135519.34847.f6

15371949


26.
Marcos
I

Borrego
S

Antinolo
G


Molecular cloning and characterization of human RAB23, a member of the group of Rab GTPases
Int J Mol Med
2003
12
983
987

14612978


27.
Marsee
DK

Vadysirisack
DD

Morrison
CD

Prasad
ML

Eng
C

Duh
QY

Rauen
KA

Kloos
RT

Jhiang
SM


Variable expression of Coxsackie–adenovirus receptor in thyroid tumors: implications for adenoviral gene therapy
Thyroid
2005
15
977
987
10.1089/thy.2005.15.977

16187905


28.
Mazzanti
C

Zeiger
MA

Costouros
NG

Umbricht
C

Westra
WH

Smith
D

Somervell
H

Bevilacqua
G

Alexander
HR

Libutti
SK


Using gene expression profiling to differentiate benign versus malignant thyroid tumors
Cancer Res
2004
64
2898
2903
10.1158/0008-5472.CAN-03-3811

15087409


29.
Mitselou
A

Vougiouklakis
TG

Peschos
D

Dallas
P

Boumba
VA

Agnantis
NJ


Immunohistochemical study of the expression of S-100 protein, epithelial membrane antigen, cytokeratin and carcinoembryonic antigen in thyroid lesions
Anticancer Res
2002
22
1777
1780

12168868


30.
Namba
H

Nakashima
M

Hayashi
T

Hayashida
N

Maeda
S

Rogounovitch
TI

Ohtsuru
A

Saenko
VA

Kanematsu
T

Yamashita
S


Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers
J Clin Endocrinol Metab
2003
88
4393
4397
10.1210/jc.2003-030305

12970315


31.
Nartey
N

Cherian
MG

Banerjee
D


Immunohistochemical localization of metallothionein in human thyroid tumors
Am J Pathol
1987
129
177
182

3661677


32.
Nikiforova
MN

Ciampi
R

Salvatore
G

Santoro
M

Gandhi
M

Knauf
JA

Thomas
GA

Jeremiah
S

Bogdanova
TI

Tronko
MD

Fagin
JA

Nikiforov
YE


Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas
Cancer Lett
2004
209
1
6
10.1016/j.canlet.2003.12.004

15145515


33.
Ofner
D

Maier
H

Riedmann
B

Bammer
T

Rumer
A

Winde
G

Bocker
W

Jasani
B

Schmid
KW


Immunohistochemical metallothionein expression in colorectal adenocarcinoma: correlation with tumour stage and patient survival
Virchows Arch
1994
425
491
497
10.1007/BF00197552

7850073


34.
Rangel
LB

Agarwal
R

Sherman-Baust
CA

Mello-Coelho
V

Pizer
ES

Ji
H

Taub
DD

Morin
PJ


Anomalous expression of the HLA-DR alpha and beta chains in ovarian and other cancers
Cancer Biol Ther
2004
3
1021
1027

15467430


35.
Santoro
M

Carlomagno
F

Hay
ID

Herrmann
MA

Grieco
M

Melillo
R

Pierotti
MA

Bongarzone
I

Della Porta
G

Berger
N

Peix
JL

Paulin
C

Fabien
N

Vecchio
G

Jenkins
RB

Fusco
A


Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype
J Clin Invest
1992
89
1517
1522

1569189


36.
Schmid
KW

Greeff
M

Hittmair
A

Totsch
M

Ofner
D

Dockhorn-Dworniczak
B

Bocker
W

Jasani
B


Metallothionein expression in normal, hyperplastic, and neoplastic thyroid follicular and parafollicular C cells using monoclonal antimetallothionein antibody E9
Endocr Pathol
1994
5
114
122

Schmid KW, Greeff M, Hittmair A, Totsch M, Ofner D, Dockhorn-Dworniczak B, Bocker W, Jasani B (1994) Metallothionein expression in normal, hyperplastic, and neoplastic thyroid follicular and parafollicular C cells using monoclonal antimetallothionein antibody E9. Endocr Pathol 5:114–122 

37.
Sheils
OM

O’Leary
JJ

Uhlmann
V

Lattich
K

Sweeney
EC


ret/PTC-1 activation in Hashimoto thyroiditis
Int J Surg Pathol
2000
8
185
189

11493988


38.
Sheils
OM

Sweeney
EC


TSH receptor status of thyroid neoplasms-TaqMan RT-PCR analysis of archival material
J Pathol
1999
188
87
92
10.1002/(SICI)1096-9896(199905)188:1<87::AID-PATH322>3.0.CO;2-5

10398146


39.
Smyth
P

Finn
S

Cahill
S

O’Regan
E

Flavin
R

O’Leary
JJ

Sheils
O


ret/PTC and BRAF act as distinct molecular, time-dependant triggers in a sporadic Irish cohort of papillary thyroid carcinoma
Int J Surg Pathol
2005
13
1
8

15735849


40.
Stolf
BS

Abreu
CM

Mahler-Araujo
MB

Dellamano
M

Martins
WK

Carvalho
MB

Curado
MP

Diaz
JP

Fabri
A

Brentani
H

Carvalho
AF

Soares
FA

Kowalski
LP

Hirata
R

Reis
LF


Expression profile of malignant and non-malignant diseases of the thyroid gland reveals altered expression of a common set of genes in goiter and papillary carcinomas
Cancer Lett
2005
227
59
73
10.1016/j.canlet.2004.11.050

16051032


41.
Tanaka
M

Adzuma
K

Iwami
M

Yoshimoto
K

Monden
Y

Itakura
M


Human calgizzarin; one colorectal cancer-related gene selected by a large scale random cDNA sequencing and Northern blot analysis
Cancer Lett
1995
89
195
200
10.1016/0304-3835(94)03687-E

7889529


42.
Thomas
GA

Bunnell
H

Cook
HA

Williams
ED

Nerovnya
A

Cherstvoy
ED

Tronko
ND

Bogdanova
TI

Chiappetta
G

Viglietto
G

Pentimalli
F

Salvatore
G

Fusco
A

Santoro
M

Vecchio
G


High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant
J Clin Endocrinol Metab
1999
84
4232
4238
10.1210/jc.84.11.4232

10566678


43.
Turk
B

Turk
D

Turk
V


Lysosomal cysteine proteases: more than scavengers
Biochim Biophys Acta
2000
1477
98
111

10708852


44.
Villadangos
JA

Bryant
RA

Deussing
J

Driessen
C

Lennon-Dumenil
AM

Riese
RJ

Roth
W

Saftig
P

Shi
GP

Chapman
HA

Peters
C

Ploegh
HL


Proteases involved in MHC class II antigen presentation
Immunol Rev
1999
172
109
120
10.1111/j.1600-065X.1999.tb01360.x

10631941


45.
Williams
ED


Two proposals regarding the terminology of thyroid tumors
Int J Surg Pathol
2000
8
181
183

11493987


46.
Yano
Y

Uematsu
N

Yashiro
T

Hara
H

Ueno
E

Miwa
M

Tsujimoto
G

Aiyoshi
Y

Uchida
K


Gene expression profiling identifies platelet-derived growth factor as a diagnostic molecular marker for papillary thyroid carcinoma
Clin Cancer Res
2004
10
2035
2043
10.1158/1078-0432.CCR-0807-03

15041723


47.
Yu
M

Xu
M

Savas
L

Khan
A


Discordant expression of Ii and HLA-DR in thyrocytes: a possible pathogenetic factor in Hashimoto’s thyroiditis
Endocr Pathol
1998
9
201
208

12114710





